Urinary cGMP concentrations in severe primary pulmonary hypertension
Why the study?
Can urinary cGMP concentrations serve as a non-invasive marker of haemodynamic impairment in patients with severe primary pulmonary hypertension?
Population
19 consecutive patients with primary pulmonary hypertension, 7 patients with acute asthma, and 30 normal…
Comparison
Measurement of urinary cyclic guanosine… vs Patients with acute asthma and normal healthy…
Design
Cross-sectional
Authors
Discussion
Loading...
Member takes
Implication
May support urinary cGMP as non-invasive marker of haemodynamic severity in PPH; leaves open clinical utility pending prospective validation.
Structured PICO
Can urinary cGMP concentrations serve as a non-invasive marker of haemodynamic impairment in patients with severe primary pulmonary hypertension?
P
Population
19 consecutive patients with primary pulmonary hypertension (PPH), 7 patients with acute asthma, and 30 normal healthy controls (total n=56).
I
Intervention
Measurement of urinary cyclic guanosine monophosphate (cGMP) concentrations.
C
Comparator
Patients with acute asthma and normal healthy controls; also comparison within PPH patients based on haemodynamic severity.
O
Outcome
Urinary cGMP concentrations and their correlation with haemodynamic parameters (cardiac index and venous oxygen saturation).surrogate
Urinary cGMP concentrations are elevated in primary pulmonary hypertension and correlate with haemodynamic severity, suggesting potential as a non-invasive monitoring biomarker.
Cite This Study
Bogdan et al. (1998) studied this question.